Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03

PURPOSE: Rituximab maintenance therapy has been shown to improve progression-free survival in patients with follicular lymphoma; however, the optimal duration of maintenance treatment remains unknown. PATIENTS AND METHODS: Two hundred seventy patients with untreated, relapsed, stable, or chemotherap...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Taverna, Christian, Martinelli, Giovanni, Hitz, Felicitas, Mingrone, Walter, Pabst, Thomas, Cevreska, Lidija, del Giglio, Auro, Vanazzi, Anna, Laszlo, Daniele, Raats, Johann, Rauch, Daniel, Vorobiof, Daniel A., Lohri, Andreas, Biaggi Rudolf, Christine, Rondeau, Stéphanie, Rusterholz, Corinne, Heijnen, Ingmar A.F.M., Zucca, Emanuele, Ghielmini, Michele
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2016
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872010/
https://ncbi.nlm.nih.gov/pubmed/26712227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.61.3968
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares